Szymon Plewa1, Agnieszka Horała2, Paweł Dereziński1, Ewa Nowak-Markwitz2, Jan Matysiak1, Zenon J Kokot3. 1. Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 6 Grunwaldzka Street, 60-780 Poznan, Poland. 2. Gynecologic Oncology Department, Poznan University of Medical Sciences, 33 Polna Street, 60-535 Poznan, Poland. 3. Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 6 Grunwaldzka Street, 60-780 Poznan, Poland. Electronic address: zkokot@ump.edu.pl.
Abstract
AIMS: Despite of almost a hundred years of research on cancer metabolism, the biological background of cancerogenesis and cancer-related reprogramming of metabolism remains not fully understood. In order to comprehensively and effectively diagnose and treat the deadliest diseases, the mechanisms underlying these diseases have to be discovered urgently. Among the gynecological malignancies, ovarian cancer is the most common cause of death. The aim of the study was to search for potential cancer-related differences in concentrations of metabolites and interactions between them in serum of women with ovarian cancer and benign ovarian tumor in comparison with healthy controls using targeted metabolomics. These metabolites might serve as biomarkers in the future. MAIN METHODS: We used wide spectrum targeted metabolomics to evaluate serum concentrations of metabolites related to ovarian cancer and compared them against benign ovarian tumors and healthy controls. The measurements were performed using high performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry technique in highly-selective multiple reaction monitoring mode. KEY FINDINGS: In this study we confirmed our previous findings about the role of histidine and citrulline in ovarian cancer as well as we indicated new lipid compounds (lysoPC a C16:1, PC aa C32:2, PC aa C34:4 and PC aa C 36:6) potentially involved in cancer metabolism. SIGNIFICANCES: We indicated interesting interactions between metabolites for further in-depth research which could potentially serve as clinically useful biomarkers in future. Moreover, the presented work attempts to visualize a possible 3D-network of relationships between the molecules found to be related to ovarian malignancy.
AIMS: Despite of almost a hundred years of research on cancer metabolism, the biological background of cancerogenesis and cancer-related reprogramming of metabolism remains not fully understood. In order to comprehensively and effectively diagnose and treat the deadliest diseases, the mechanisms underlying these diseases have to be discovered urgently. Among the gynecological malignancies, ovarian cancer is the most common cause of death. The aim of the study was to search for potential cancer-related differences in concentrations of metabolites and interactions between them in serum of women with ovarian cancer and benign ovarian tumor in comparison with healthy controls using targeted metabolomics. These metabolites might serve as biomarkers in the future. MAIN METHODS: We used wide spectrum targeted metabolomics to evaluate serum concentrations of metabolites related to ovarian cancer and compared them against benign ovarian tumors and healthy controls. The measurements were performed using high performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry technique in highly-selective multiple reaction monitoring mode. KEY FINDINGS: In this study we confirmed our previous findings about the role of histidine and citrulline in ovarian cancer as well as we indicated new lipid compounds (lysoPC a C16:1, PC aa C32:2, PC aa C34:4 and PC aa C 36:6) potentially involved in cancer metabolism. SIGNIFICANCES: We indicated interesting interactions between metabolites for further in-depth research which could potentially serve as clinically useful biomarkers in future. Moreover, the presented work attempts to visualize a possible 3D-network of relationships between the molecules found to be related to ovarian malignancy.
Authors: Marie Breeur; Pietro Ferrari; Laure Dossus; Mazda Jenab; Mattias Johansson; Sabina Rinaldi; Ruth C Travis; Mathilde His; Tim J Key; Julie A Schmidt; Kim Overvad; Anne Tjønneland; Cecilie Kyrø; Joseph A Rothwell; Nasser Laouali; Gianluca Severi; Rudolf Kaaks; Verena Katzke; Matthias B Schulze; Fabian Eichelmann; Domenico Palli; Sara Grioni; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Bas Bueno-de-Mesquita; Karina Standahl Olsen; Torkjel Manning Sandanger; Therese Haugdahl Nøst; J Ramón Quirós; Catalina Bonet; Miguel Rodríguez Barranco; María-Dolores Chirlaque; Eva Ardanaz; Malte Sandsveden; Jonas Manjer; Linda Vidman; Matilda Rentoft; David Muller; Kostas Tsilidis; Alicia K Heath; Hector Keun; Jerzy Adamski; Pekka Keski-Rahkonen; Augustin Scalbert; Marc J Gunter; Vivian Viallon Journal: BMC Med Date: 2022-10-19 Impact factor: 11.150
Authors: M V Iurova; V V Chagovets; S V Pavlovich; N L Starodubtseva; G N Khabas; K S Chingin; A O Tokareva; G T Sukhikh; V E Frankevich Journal: Front Mol Biosci Date: 2022-04-14